The Impact of Pre-exisiting SIV on Host Immunity to M tuberculosis in Macaques

先前存在的 SIV 对猕猴结核分枝杆菌宿主免疫的影响

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (Mtb) infects over one billion people, resulting in 9 million cases of tuberculosis (TB) annually, and over 1 million deaths each year. The majority of Mtb-infected individuals are unable to eliminate the pathogen, but can control it and establish latent TB. One of the biggest risk factors for developing active TB is co-infection with human immunodeficiency virus (HIV). Recent studies have shown that the majority of co-infected individuals are infected with HIV first and subsequently co-infected with Mtb. T cell responses play a critical role in containing Mtb, so it is not surprising that immunodeficient HIV+ individuals are likely to develop active TB. Notably, HIV+ persons on HAART or who have high CD4 counts are still more likely to develop active TB than someone who is HIV-naïve. Clearly, factors besides simply CD4 depletion in blood must contribute to the increased likelihood of active TB in co-infected individuals. Nonhuman primates infected with Mtb recapitulate all aspects of human TB, and those infected with simian immunodeficiency virus (SIV) display symptoms similar to HIV/AIDS. Using SIV+ Mauritian cynomolgus macaques (MCM), we will identify the mechanism by which pre-existing SIV infection interferes with host control over an Mtb infection. We hypothesize that SIV impairs the early Th1 and Th17 cytokine response by T cells in granulomas, which prevents control of Mtb replication. To test this hypothesis, we will track epitope-specific T cells with tetrameric molecules in the blood and granuloma lesions of MCM co-infected with SIV and Mtb. We will also use state-of-the-art PET/CT imaging to characterize the early formation of granulomas in lung tissue of SIV+ animals after Mtb co-infection. Lastly, we will determine if a novel subunit TB vaccine can boost cellular immune responses in SIV+ animals and re- establish the ability to control a subsequent Mtb challenge. This proposal brings together two investigators with complimentary expertise to provide new insights into the events that impair control of Mtb infection in the setting of pre-existing HIV infection. Novel studies in a highly relevant animal model will lead to an understanding of the critical events in early Mtb infection that prevent establishment of latent TB and will evaluate the potential of boosting immunity to Mtb in SIV+ animals.
 描述(由申请人提供): 结核分枝杆菌(Mycobacterium tuberculosis,Mtb)感染超过10亿人,每年导致900万结核病(TB)病例,并且每年导致超过100万人死亡。大多数结核病感染者无法消除病原体,但可以控制它并建立潜伏性结核病。发展活动性结核病的最大风险因素之一是合并感染人类免疫缺陷病毒(HIV)。最近的研究表明,大多数合并感染者首先感染艾滋病毒,随后合并感染结核分枝杆菌。T细胞反应在遏制Mtb方面起着关键作用,因此免疫缺陷的HIV+个体可能发展为Mtb并不奇怪。 活动性肺结核值得注意的是,接受高效抗逆转录病毒疗法的艾滋病毒阳性者或CD 4计数高的人仍然比艾滋病毒初治者更有可能发展为活动性结核病。显然,除了血液中CD 4的简单消耗外,其他因素也会导致合并感染个体活动性结核病的可能性增加。感染结核分枝杆菌的非人灵长类动物再现了人类结核病的所有方面,而感染猿猴免疫缺陷病毒(SIV)的灵长类动物则表现出类似于HIV/AIDS的症状。使用SIV+猕猴(MCM),我们将确定预先存在的SIV感染干扰宿主控制结核分枝杆菌感染的机制。我们假设SIV损害肉芽肿中T细胞的早期Th 1和Th 17细胞因子应答,这阻止了Mtb复制的控制。为了验证这一假设,我们将用四聚体分子追踪SIV和Mtb共感染的MCM的血液和肉芽肿病变中的表位特异性T细胞。我们还将使用最先进的PET/CT成像来表征Mtb共感染后SIV+动物肺组织中肉芽肿的早期形成。最后,我们将确定一种新的亚单位结核病疫苗是否可以增强SIV+动物的细胞免疫应答,并重新建立控制随后Mtb攻击的能力。该提案汇集了两名具有互补专业知识的研究人员,为在既存艾滋病毒感染的情况下损害结核分枝杆菌感染控制的事件提供新的见解。在高度相关的动物模型中进行的新研究将有助于了解早期Mtb感染中防止潜伏性TB建立的关键事件,并将评估在SIV+动物中增强对Mtb免疫力的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles A. Scanga其他文献

Markov field network model of multi-modal data predicts effects of immune system perturbations on intravenous BCG vaccination in macaques
多模态数据的马尔可夫场网络模型预测免疫系统扰动对猕猴静脉注射卡介苗接种的影响
  • DOI:
    10.1016/j.cels.2024.10.001
  • 发表时间:
    2024-12-18
  • 期刊:
  • 影响因子:
    7.700
  • 作者:
    Shu Wang;Amy J. Myers;Edward B. Irvine;Chuangqi Wang;Pauline Maiello;Mark A. Rodgers;Jaime Tomko;Kara Kracinovsky;H. Jacob Borish;Michael C. Chao;Douaa Mugahid;Patricia A. Darrah;Robert A. Seder;Mario Roederer;Charles A. Scanga;Philana Ling Lin;Galit Alter;Sarah M. Fortune;JoAnne L. Flynn;Douglas A. Lauffenburger
  • 通讯作者:
    Douglas A. Lauffenburger
Evaluating the effect of clofazimine against emMycobacterium tuberculosis/em given alone or in combination with pretomanid, bedaquiline or linezolid
评估氯法齐明单独或与普特曼定、贝达喹啉或利奈唑胺联合使用对结核分枝杆菌的疗效
  • DOI:
    10.1016/j.ijantimicag.2021.106509
  • 发表时间:
    2022-02-01
  • 期刊:
  • 影响因子:
    4.600
  • 作者:
    Sarah Kim;Arnold Louie;George L. Drusano;Mohammed Almoslem;Soyoung Kim;Jenny Myrick;Jocelyn Nole;Brandon Duncanson;Charles A. Peloquin;Charles A. Scanga;Walter Yamada;Michael Neely;Stephan Schmidt
  • 通讯作者:
    Stephan Schmidt

Charles A. Scanga的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles A. Scanga', 18)}}的其他基金

Preventing TB with intravenous BCG in SIV-infected macaques
在感染 SIV 的猕猴中静脉注射卡介苗预防结核病
  • 批准号:
    10401493
  • 财政年份:
    2021
  • 资助金额:
    $ 75.12万
  • 项目类别:
Preventing TB with intravenous BCG in SIV-infected macaques
在感染 SIV 的猕猴中静脉注射卡介苗预防结核病
  • 批准号:
    10257052
  • 财政年份:
    2021
  • 资助金额:
    $ 75.12万
  • 项目类别:
Preventing TB with intravenous BCG in SIV-infected macaques
在感染 SIV 的猕猴中静脉注射卡介苗预防结核病
  • 批准号:
    10610411
  • 财政年份:
    2021
  • 资助金额:
    $ 75.12万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.12万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了